[
  {
    "objectID": "posts/post-with-code/collagen_outcomes/collagen_and_cartilage_joints_muscle_skin_outcomes_refined_blog.html",
    "href": "posts/post-with-code/collagen_outcomes/collagen_and_cartilage_joints_muscle_skin_outcomes_refined_blog.html",
    "title": "Collagen Outcomes on Cartilage, Joints, Muscle, and Skin Outcomes",
    "section": "",
    "text": "My Foray into the World of Collagen\nI have to admit something.\n\nBefore doing the research for this article, I wasn‚Äôt expecting to dive into collagen much. It seemed like just another supplement touted by random influencers online for everything from joint health to skin health to basically everything in between involving a connective tissue.\n\nLike most noise on social media about random supplements, I chose to ignore it.\nThis changed though when a couple of different doctors I knew started recommending I consume it too. I was surprised it had made its way into their clinical recommendations.\n\nThough I still felt quite indifferent towards the product, it pushed me just enough in the direction of me doing my own searching, for nothing more than not having to think about collagen again.\n\nGoing in, I had a few important considerations for any trial evaluating collagen that I wanted to see fulfilled:\n\nAssessment and control for protein intake at baseline for all groups (especially in older adults). You would get many bonus points if you ensured an slightly higher protein intake of at least 1.2g/kg lean mass in an isonitrogenic fashion between control and treatment arms. Given that collagen obviously contributes to our amino acid pool when it‚Äôs digested, and the generally well known benefits on sufficient total protein intake for bone, muscle, and connective tissue health, this seemed like a very important consideration to me.¬†\nConsistent dosages of the same molecules and consistent length of supplementation. This allows for a better understanding of what dose, collagen type, and exposure time length we can obtain benefits from if they are to be had.\nEither the collagen is a standalone intervention and compared to a placebo that‚Äôs isonitrogenic, or have the treatment assignments be something like¬†the following:\n\n\n\n\nTreatment\nControl\n\n\n\n\nHydrolyzed Collagen\nIsonitrogenic Placebo\n\n\nHyaluronic Acid\nHyaluronic Acid\n\n\nGlucosamine\nGlucosamine\n\n\nCondroiton\nCondroiton\n\n\n\nWhere the only difference between treatment and control is the collagen supplement, but some standard of care treatment is included.\nWith those ground rules set, I‚Äôd like to present my synthesis on collagen‚Äôs outcome data for various endpoints. In no particular order I‚Äôll be going over higher level meta analyses and systemic reviews and working my way down into commenting on individual trials cited in these reviews.\n\n\nA look into the Systematic Reviews and Meta Analyses on Collagen\n2024 Meta Analysis/Systematic Review looking at a variety of outcome\n\n‚ÄúAims to investigate the effects of long-term daily collagen peptide (CP) supplementation on strength, musculotendinous adaptation, functional recovery, and body composition in healthy adults‚Äù.\nLooked at outcomes measuring fat-free mass, tendon morphology, muscle mass, maximal strength, and recovery in reactive strength following exercise-induced muscle damage.\nPRISMA chart shows 19 studies that were included with over 768 total participants\nThe meta analysis authors used Standardized Mean Difference as the outcome measure. I maintain that most meta analyses nowadays shouldn‚Äôt be using it unless they can give a clear definition of the underlying construct that they‚Äôre trying to measure. The definition of the estimand for the meta analyses, is what leads to clear definitions of the construct used for the SMD. it‚Äôs a vital part of the process that most meta analyses using SMD don‚Äôt seem to do for whatever reason. SMD has almost no proper use case for a meta analysis these days and should only be used by a very very very experienced practitioner\nWhy is the second criteria of the meta analyses inclusion criteria that ‚Äúthey used different forms of DC (dietary collagen)‚Äù? If they simply mean using a variety of collagen molecules but in similar proportions and dosages across studies, I have no problem. But I‚Äôm not sure based on the wording here.(To be fair, many of the trials stuck to 15g daily DC supplementation).¬†\nIf I‚Äôm not mistaken, literally only one trial provided a protein matched placebo. Only ONE!!!!! The rest were some combination of maltodextrin, dextrose, or some random white powder that mixes similar to collagen in water.\nThey keep stacking people from the same study multiple times into the same forest plot. Wtf why??? Just make different subgroup analyses! THIS MAKES THE EFFECT MEASURE UNINTERPRETABLE. Not that SMD in this context wasn‚Äôt borderline uninterpretable from the start. Case in point:\n\n- \n- \nThe literal definition of what not to do in a forest plot, right there. This entire paper is just best ignored at this point.\nFor fun, I tried to see if I can even replicate the above forest plot with the details they gave, but I decided it was too much effort when even the n they reported for the Oertzen study in the forest plot (91) didn‚Äôt match with the actual n reported.\nSupplemental Collagen Meta Analysis Done for osteoarthritis outcomes (using the VAS as the main outcome)¬†\n\nMeta analysis of 6 studies with over 300 patients.\nI wanted to note this letter because the author succinctly commentates on some of the issues I‚Äôm observing with this literature.\nTo the author‚Äôs point about financial biases: Unlike him, I want to note I personally don‚Äôt really care about who funded a study. As long as the results are analytically valid and study design is sound I have no problems who funded it, as they‚Äôd be valid independent of funding. Typically if there are nefarious things at play from the financial bias of the funders then they show up in study design, methods, and interpretations and you can criticize the study on the merit of those\nThe author notes problems in this meta analysis around inconsistent dosage, effect sizes, possible publication bias,length of usage and actual clinical significance which are all very very fair criticisms and ones I agree with. This is unfortunately a theme we‚Äôll see going throughout today‚Ä¶..¬†\n\nWe do happen to have a couple of broad Systematic Reviews on the topic of supplementary collagen for cartilages, joints and muscles! Great!! Let‚Äôs read further‚Ä¶..\nRole of Collagen Derivatives in Osteoarthritis and Cartilage Repair: A Systematic Scoping Review With Evidence Mapping\n\n41 published studies were ultimately included in the review, 16 of which were preclinical studies and 25 were clinical studies (including four systematic reviews/meta-analyses)\nOh dear god, these didn‚Äôt list baseline protein intakes of people in the study in the review (making me have to go through each trial to find if they did)¬†\n\nTherefore I hate my life and these researchers I hate even more¬†\n\nAt a glance, wildly varying doses of collagen, different molecular weights, whether it‚Äôs hydrolyzed, varying trial lengths. This is a red flag.\nAlso for some reason smaller studies seem to consistently show higher effect sizes¬†than larger ones. This is also another red flag.\nWe‚Äôll end up diving into some of the issues these individual studies had in the next section. The errors found in those individual studies are broadly representative of the problems the rest of them in this review have. I‚Äôve definitely come to a different conclusion about collagen than these authors.\n\nThe effects of collagen peptide supplementation on body composition, collagen synthesis, and recovery from joint injury and exercise: a systematic review\n\nOnly two studies had a placebo that matched total protein in the placebo. Again‚Ä¶..why would you do something like this?\nAnd both of those that did have a comparable protein placebo they measured the surrogate outcome MPS, instead of hard outcomes like body composition or joint pain, cartilage size/thickness, etc. So there‚Äôs no real conclusion on hard outcomes to be made here.\nDo I even want to bother with looking at the randomization + power analyses for both of these‚Ä¶.I know I‚Äôm not going to be happy at a glance. Let‚Äôs spare myself the mental burden\nHere‚Äôs a trial from the reviewe where it‚Äôs unclear whether the difference in VAS is clinically significant (&lt; 10): https://cdnsciencepub.com/doi/10.1139/apnm-2016-0390\n\nAgain, no assessment of baseline protein intake nor were the treatment and control protein matched. So‚Ä¶‚Ä¶‚Ä¶..we move on.\n\n\nEffects of Oral Collagen on Skin Aging Parameters\n\nThis meta analysis seems to be the most commonly cited one for the benefits of oral collagen on skin aging outcomes. They meta analyzed 26 RCTs with 1721 patients for a variety of skin related outcomes, like Trans Epidermal Water Loss (TEWL), elasticity, hydration, wrinkles, dermal density, and many more.\nUnlike the previous meta before, they did many more of the basic minimum things right compared to the metas I‚Äôve cited earlier in this review. But there are still many basic errors to highlight here‚Ä¶.\nThis is yet another meta analysis that has forest plots using SMD improperly. Though they did have a meta analyst statistician specialist on this meta, it tends to be the researchers‚Äô faults for being lazy and not doing the unit coversions when appropriate such that Mean Difference can be used.\nThe forest plots at least do a good job of separating time points and other relevant categorizations into somewhat appropriate subgroup analyses. (I can‚Äôt believe I have to offer such a basic point as legitimate praise)\nImportant to note that this meta was situated on trials that focused mainly in older woman between 35 - 60 years of age.\nOn the forest plot‚Äôs face value, it seems collagen is pretty consistently positively associated with most skin aging metrics here. That said when the metric is SMD it‚Äôs hard to interpret what the outcome even means. It gets worse‚Ä¶.\n\n\nSo many heterogeneous interventions with respect to dose and type of collagen.¬†This further estranges how the SMD could be interpreted, and is a red flag.\n\nThis is also an example from one of the trials:\n\n\nOn top of the standard criticism of not matching for protein in the placebo nor having any evaluation of baseline dietary protein intake‚Ä¶‚Ä¶.The intervention isn‚Äôt even just collagen ALONE but a host of different things. How can we know the unique total protein independent content effect of collagen when you have all these other things?\n\nYet another study from this meta that didn‚Äôt protein match in the placebo nor give baseline protein intakes. They also didn‚Äôt use ANCOVA, or change scores even to analyze. Plus significance testing variables at baseline‚Ä¶..noobs \n\n\nThis meta keeps continuing tradition from the other top level reviews with the inclusion of a trial that didn‚Äôt use a protein controlled placebo or assessed protein intake at baseline. Which is sad because this trial did a better job of explaining their randomization protocols and power analysis better than most!! (only thing missing was explaining their minimum effect size clearly)\n\nThey did do subgroup analyses for the source of the collagen (what animal) and for supplementation length and different outcomes‚Ä¶.but it‚Äôs hard to make super robust conclusions here. Especially given their lack of accounting for protein intake and placebo protein control. But if you had to make me flip a coin, I might lean slightly in favor of collagen being beneficial for skin aging markers. But barely so.\n\nOverall if there‚Äôs a possible benefit to be had from collagen, the strongest evidence is in skin it seems.¬†But there are still some fundamental issues with this meta that I‚Äôve highlighted above that greatly diminish my confidence in the results for skin. I also think it‚Äôs responsible for me to admit that I‚Äôm not as equipped to evaluate inclusion criteria in these studies, as well as knowing what clinical significance is for a lot of these metrics. I‚Äôll do best consulting a researcher that is more familiar with skin, and update this section.\n\n\nA Closer Look at Individual Studies\nWhey protein vs leucine matched collagen protein RCT\n\nThis is a paper from the above muscle health meta, but SciHub doesn‚Äôt have access unfortunately :(. If I‚Äôm to believe just their results without looking at the methods then at least for muscle size whey protein does better than leucine matched collagen. Though I‚Äôm sure I‚Äôd have problems with this trial if I actually read it üòÖ\n\nSkin Health + Elasticity with a (collagen + hyaluronic acid +other molecules) supplement l\n\n120 participants randomized between each group, randomization method most likely simple given the website tool cited even though they said they randomized the patients ‚Äúon the basis of the following characteristics: age, sex, BMI, ethnic background (mainly Caucasian),smoking habits, alcohol intake, nutritional level, and skin type assessed using Fitzpatrick scale‚Äù. Which‚Ä¶ would imply stratified sampling???? But the randomization website tool they used didn‚Äôt allow for stratified sampling lol this is a red flag for the competence of these researchers\nEveryone was blinded till end of study\nNot clear they powered for their what was most likely post-hoc subgroup comparisons of older adults for joints. they took like 18 out of 34 people in the older age group who scored high on a joint pain assessment and looked at their outcomes. Common mistake here\nNo assessment for protein intake at baseline nor a protein matched placebo\nye bhagavan why do I even bother¬†\n\nEffect of the Novel Low Molecular Weight Hydrolyzed Chicken Sternal Cartilage Extract, BioCell Collagen, on Improving Osteoarthritis-Related Symptoms: A Randomized,Double-Blind,Placebo-Controlled Trial¬†\n\nLiterally nothing on power analysis (big big red flag)\nNo assessment of baseline protein intake, AGAIN. It‚Äôs like they‚Äôre all trying to prove me right with how incompetent they are.¬†\nSame bullshit that didn‚Äôt assess collagen by itself but with Hyaluronic Acid and Chondroitin in conjunction compared to a placebo with nothing in it (not protein matched)\nLet‚Äôs move on this trial is a waste of my time and headspace already there‚Äôs nothing of value here\n\nThis Ecuadorian study may be best so far because they measured a proxy for protein intake and included this in the analysis in some form.\n\nProper description of some aspects of their power analysis (*victory dance*)\nSome aspects of randomization described (*victory dance*)\nHigher sample size than others which is always nice\nThey used change scores instead of using the standard ANCOVA and adjusting for baseline, which is generally the best statistical approach for this (so get dinged slightly some points for that)\nDid a subgroup for high meat intake to account for effects in people with higher dietary collagen (over 1549 grams of meat per week versus under 1549 grams of meat per week, which if we assume is lean ground beef 1549 grams averaged over the week amounts to around ~55g protein per day and somewhere between 5-20g collagen per day)\nWhy do these people keep dichotomizing continuous variables on the median I beg you clinicians please stop dichotomizing continuous variables in your research you‚Äôre throwing valuable information and variance away for no good reason. There are ways to make use of the information kept when it remains continuous so that it remains informative!!!\nThe higher meat intake group is supposed to measure dietary collagen intake and how much that contributes to the outcome, but that will also track with total protein intake for obvious reasons¬†\nIf this is the best study I‚Äôve found I don‚Äôt have much faith in humanity anymore\nIs the following difference for VAS even clinically significant? Look how attenuated the difference is with the higher meat group\n\nAnother Chinese study looking at collagen hydrosalate\n\nPower Analysis consists of this sentence:\n‚ÄúThis effect size assures, at a significance level of a=0.05, a power of 90% for WOMAC score, and of more than 80% for Lysholm score‚Äù. Without sharing what ‚Äúthis effect size‚Äù meant.¬†\n\nWho‚Äôs the genius that came up with this masterful phrasing that makes up the power analysis????? (I hope the sarcasm is dripping through)¬†\nSeriously again these researchers are a joke and deserve to be publicly stoned (obviously I‚Äôm kidding don‚Äôt report me)\n\nOnce again‚Ä¶..didn‚Äôt assess baseline protein intake nor is the placebo protein matched. Another completely fatal flaw.\n\n\n\n\nMy Final Conclusions on the Topic\nYes, after checking out the primary high level tiers of evidence and skimming over what I didn‚Äôt read in depth, I‚Äôve lost pretty much all faith that most, if any, of these can be redeemed. I need them to assess for baseline protein intake and have the placebo total protein matched AT A MINIMUM but I have only encountered like 2-3 that did that, with 2 of them assessing MPS only (lol) and the last one uvailable to read (also it‚Äôs an incredibly small study).¬†\nThus almost none of them are equipped to interpret collagen‚Äôs effect on the body, independent of its protein content. I think I‚Äôm done here.\nUpdate: My friend has informed me that there‚Äôs actually some decent evidence for isolated glycine (one of the primary amino acid constituents of collagen, along with proline and isoproline) for various endpoints. When he provides me with those papers, I‚Äôll talk about it on this blog and we can see if there are any benefits of collagen if they are to be had but taking in glycine directly instead. We shall see.\nAt present, it‚Äôs not clear collagen is good for much beyond the protein content (except for maybe skin aging if you‚Äôre a older woman with skin aging?), and I‚Äôd just recommend getting enough protein (1-1.2 g protein/kg lean body mass, if being conservative up to 1.6g/kg daily for older adults). Getting the total protein intake to at least 1g/kg lean mass is pretty broadly important for overall health.\n\nIf you find 1.2g/kg hard, protein supplements are an excellent way to get up to that number, and using plain soy protein isolate for example is much more versatile than people think. Protein rich legumes like soy and lupini beans are great. Soy itself is very versatile as high protein options like tofu, tempeh, and TVP exist. Seitan is a real showstopper as well, since the protein to calorie ratio is off the charts and it is usually quite cheap to buy and store in bulk. There are lots of creative ways to up protein intake, and really going from 0.6 g/kg protein to 1g/kg protein goes such a long way. Don‚Äôt stress out over going above and beyond in protein intake if it‚Äôs causing stress and is leading to a less palatable diet. You‚Äôve done most of the work by getting to 1g protein/kg lean mass.\n\nI do think it is unfortunate that we have to worry about getting this much protein in the first place. It is a stroke of bad luck, and if humans needed like half the protein intake to capitalize on muscle, bone, skin and joint health, our collective lives would be so much easier. But, alas the overall outcome data on protein paints a different picture than I would like, and I plan to be honest with everyone else."
  },
  {
    "objectID": "blog.html",
    "href": "blog.html",
    "title": "Makarand Nadendla",
    "section": "",
    "text": "--- listing:   \ncontents: posts/**/*.qmd   \nsort: \"date desc\"   \ntype: default   \ncategories: true   \nsort-ui: true   \nfilter-ui: true   \nfields: [date, title, reading-time, description, categories]   \npage-layout: full \ntitle-block-banner: false \n---"
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About",
    "section": "",
    "text": "Join me as I muse about statistical and causal inference in modern AI/ML, as well as medical and nutritional epidemiology."
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Biostatistics and Causal Inference",
    "section": "",
    "text": "Collagen Outcomes on Cartilage, Joints, Muscle, and Skin Outcomes\n\n\n\n\n\n\nnews\n\n\ncode\n\n\nanalysis\n\n\n\n\n\n\n\n\n\nOct 10, 2024\n\n\nMakarand Nadendla\n\n\n\n\n\n\nNo matching items"
  }
]